InflaRx

cost cutting restructuring savings reduce spend
Pharma

InflaRx charts layoffs, cost cuts to lift lead asset's prospects

Roughly 30% of the company’s staff will be laid off, accompanied by “substantial spending reductions,” InflaRx said in its announcement.
Fraiser Kansteiner Jan 8, 2026 11:03am
game over pivot new direction

InflaRx may find path forward for COVID drug in skin disorder

Jan 2, 2026 10:25am
Missed target failed trial trial failure

InflaRx scraps vilobelimab study in rare skin disorder

May 28, 2025 9:55am
FDA

FDA authorizes InflaRx's anti-inflammation drug for severe COVID

Apr 4, 2023 5:12pm